News
MCK Stock Gains as PRISM Acquisition Adds High-Growth Business
McKesson acquires 80% ownership in PRISM Vision Holdings, diversifying its business into the high-growth area of ophthalmology. The deal is to be accretive this year.
zacks.com • Apr 03, 2025 16:00 Eastern
McKesson Shares Up Over 2% After Key Signal
MCK IS UP OVER 14 POINTS AFTER THE TRADEPULSE ALERT
benzinga.com • Apr 03, 2025 06:59 Eastern
McKesson Gets Drugs to Patients. Buy the Stock for Healthy Returns.
An aging U.S. population is increasing the demand for medication, and this company delivers.
barrons.com • Apr 03, 2025 01:30 Eastern
McKesson Corporation Completes Acquisition of PRISM Vision Holdings, LLC
IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) today announced the completion of its previously announced acquisition of a controlling interest in PRISM Vision Holdings, LLC, a leading provider of general ophthalmology and retina management services. McKesson acquired an approximate 80% controlling interest in PRISM Vision Holdings, an ophthalmology and retina management services provider, for about $850 million. PRISM physicians will retain an approximate 20% interest. The ac.
businesswire.com • Apr 02, 2025 08:00 Eastern
McKesson (MCK) Laps the Stock Market: Here's Why
In the most recent trading session, McKesson (MCK) closed at $672.99, indicating a +0.74% shift from the previous trading day.
zacks.com • Mar 31, 2025 19:05 Eastern
Wall Street Bulls Look Optimistic About McKesson (MCK): Should You Buy?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
zacks.com • Mar 28, 2025 10:30 Eastern
McKesson: Immune To Weak Economy And Tariffs; Top Idea In 2025
I maintain a 'Strong Buy' rating on McKesson with a fair value of $723 per share due to its robust oncology network and strong growth prospects. McKesson's minimal exposure to US-Mexico-Canada tariffs and geopolitical tensions ensures stability, making it a reliable investment amid economic uncertainties. The company's GLP-1 and oncology franchises are key growth drivers, with GLP-1 revenue growing 45% year-over-year and oncology patient visits increasing steadily.
seekingalpha.com • Mar 25, 2025 01:13 Eastern
McKesson (MCK) Stock Drops Despite Market Gains: Important Facts to Note
McKesson (MCK) closed at $660.86 in the latest trading session, marking a -0.05% move from the prior day.
zacks.com • Mar 24, 2025 18:55 Eastern